Literature DB >> 15058312

The pharmacological treatment of cachexia.

Josep M Argilés1, Vanessa Almendro, Sílvia Busquets, Francisco J López-Soriano.   

Abstract

Cachexia is a complex syndrome. The main components of this pathological state are anorexia and metabolic abnormalities such as glucose intolerance, fat depletion, and muscle protein catabolism among others. The aim of the present article is to review the different therapeutic approaches that have been designed to fight and counteract muscle wasting in different pathological states such as cancer, AIDS and chronic heart failure.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15058312     DOI： 10.2174/1389450043490505

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN： 1389-4501            Impact factor:   3.465


  9 in total

1.  The dose-dependent effects of endotoxin on protein metabolism in two types of rat skeletal muscle.

Authors:  Miroslav Kovarik; Tomas Muthny; Ludek Sispera; Milan Holecek
Journal:  J Physiol Biochem       Date:  2012-02-07       Impact factor: 4.158

2.  CREB, NF-Y and MEIS1 conserved binding sites are essential to balance Myostatin promoter/enhancer activity during early myogenesis.

Authors:  Carla Vermeulen Carvalho Grade; Carolina Stefano Mantovani; Marina Alves Fontoura; Faisal Yusuf; Beate Brand-Saberi; Lúcia Elvira Alvares
Journal:  Mol Biol Rep       Date:  2017-09-27       Impact factor: 2.316

3.  Rosiglitazone delayed weight loss and anorexia while attenuating adipose depletion in mice with cancer cachexia.

Authors:  Michelle L Asp; Min Tian; Kara L Kliewer; Martha A Belury
Journal:  Cancer Biol Ther       Date:  2011-12-01       Impact factor: 4.742

Review 4.  Symptom perception in CHF: (why mind matters).

Authors:  Christine E Skotzko
Journal:  Heart Fail Rev       Date:  2007-12-11       Impact factor: 4.214

5.  Audit of symptoms and prescribing in patients with the anorexia-cachexia syndrome.

Authors:  Inga Andrew; Graeme Kirkpatrick; Keith Holden; Colette Hawkins
Journal:  Pharm World Sci       Date:  2008-02-02

6.  Anabolic effects of a non-myotoxic dose of the beta2-adrenergic receptor agonist clenbuterol on rat plantaris muscle.

Authors:  Jatin G Burniston; Lynn McLean; Robert J Beynon; David F Goldspink
Journal:  Muscle Nerve       Date:  2007-02       Impact factor: 3.217

7.  Optimal management of cancer anorexia-cachexia syndrome.

Authors:  Josep M Argilés; Mireia Olivan; Sílvia Busquets; Francisco Javier López-Soriano
Journal:  Cancer Manag Res       Date:  2010-01-22       Impact factor: 3.989

8.  Depletion of white adipose tissue in cancer cachexia syndrome is associated with inflammatory signaling and disrupted circadian regulation.

Authors:  Maria Tsoli; Martina Schweiger; Anne S Vanniasinghe; Arran Painter; Rudolf Zechner; Stephen Clarke; Graham Robertson
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

9.  The study on mechanism of the modified Chinese herbal compound, jianpijiedu, on a mouse model of hepatic carcinoma cachexia.

Authors:  Baoguo Sun; Haoxuan Luo; Liuxiang Deng; Shijun Zhang; Zexiong Chen
Journal:  Mol Med Rep       Date:  2016-08-08       Impact factor: 2.952
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.